Castle Biosciences to Host Second Annual Castle Cares Charity Walk
18 Julho 2023 - 8:00AM
Business Wire
Castle employees to raise funds and awareness
for five partner organizations in support of patients impacted by
skin cancer, esophageal cancer, mental health conditions and uveal
melanoma
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving
health through innovative tests that guide patient care, announced
that it will host its second company-wide Castle Cares Charity Walk
today, Tuesday, July 18, 2023, in Orlando, Florida, and virtually.
Through the walk, Castle employees are raising funds for five
patient advocacy organizations, The Skin Cancer Foundation, IMPACT
Melanoma, Esophageal Cancer Action Network (ECAN), Mental Health
America (MHA) and A Cure In Sight (ACIS), in support of the patient
communities served by the Company’s innovative portfolio of
tests.
“We believe in the power of collective action and the positive
impact we can create by keeping people first, particularly the
patient communities we serve,” said Derek Maetzold, president and
chief executive officer of Castle Biosciences. “The Castle Cares
Charity Walk serves as a testament to our employees’ dedication and
the values we uphold as an organization. I am incredibly proud of
our Castle team and the great work they are doing in support of
these remarkable organizations.”
The 2022 inaugural Castle Cares Charity Walk raised more than
$11,000 for partner organizations, a goal which the Company
endeavors to exceed this year. Learn more about the organizations
Castle is supporting through its walk at the following websites:
The Skin Cancer Foundation, IMPACT Melanoma, Esophageal Cancer
Action Network (ECAN), Mental Health America (MHA) and A Cure in
Sight.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics
company improving health through innovative tests that guide
patient care. The Company aims to transform disease management by
keeping people first: patients, clinicians, employees and
investors.
Castle’s current portfolio consists of tests for skin cancers,
uveal melanoma, Barrett’s esophagus and mental health conditions.
Additionally, the Company has active research and development
programs for tests in other diseases with high clinical need,
including its test in development to predict systemic therapy
response in patients with moderate-to-severe psoriasis, atopic
dermatitis and related conditions. To learn more, please visit
www.CastleBiosciences.com and connect with us on LinkedIn,
Facebook, Twitter and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath
Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq,
TissueCypher and IDgenetix are trademarks of Castle Biosciences,
Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230718249461/en/
Investor Contact: Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact: Allison Marshall
amarshall@castlebiosciences.com
Castle Biosciences (NASDAQ:CSTL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Castle Biosciences (NASDAQ:CSTL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024